Asahi Kasei Pharma Corporation

We believe great science comes from working together.

Asahi Kasei Pharma Corporation is focused on the discovery and development of new drugs that address unmet medical needs.

January 29, 2021: Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
October 13, 2020: Asahi Kasei Pharma to solicit proposals for drug discovery research
June 2, 2020: Asahi Kasei Pharma obtains Chinese approval for Flivas™ (naftopidil) dysuria treatment
March 19, 2020: Asahi Kasei Pharma concludes license agreement with SBI Biotech for SBI-3150
January 9, 2020: Denial of motion for preliminary injunction requesting continuous supply of XIAFLEX® injection
November 27, 2019: Announcement of listing on the NHI drug price standard and marketing of Teribone™ 28.2 µg subcutaneous autoinjector
November 25, 2019: Asahi Kasei to Acquire Veloxis Pharmaceuticals Inc.
November 25, 2019: Asahi Kasei Pharma licenses fasudil to Woolsey Pharmaceuticals

Page Top